International Clinical Trial: The Dosimetry, Safety and Diagnostic Efficacy of 68Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07468708) titled 'The Dosimetry, Safety and Diagnostic Efficacy of 68Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer' on March 9.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).

Primary Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.

Condition: Healthy Adult Prostate Cancer

Intervention: Drug: 68Ga-FC516 Drug: 68Ga-FC516 and 68Ga-labeled PSMA-targeting tracer

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: March 2026

Target Sample Size: 30

Countries ...